Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Authors' conclusion
Tirzepatide has significant potential as a weight loss drug in patients with overweight and obesity, with little increase in AEs compared to other weight loss drugs. With its ability to concurrently target multiple aspects of metabolic syndrome, it should be considered as the next helm of weight loss therapies.
Study context
- Population
- Patients with overweight or obesity
- Participants
- 5,800 patients
- Comparison
- Tirzepatide vs control
- Outcome
- ≥5%, ≥10% and ≥15% weight loss, and AEs (single-arm meta-analysis of proportions)
Methodological detailssingle-arm meta-analysis of proportions, comparative meta-analysis, Medline, Embase and Cochrane CENTRAL searched for randomized controlled trials (RCTs)
- Single-arm meta-analysis of proportions
- Comparative meta-analysis
- Medline, Embase and Cochrane CENTRAL searched for RCTs
Pooled result
As reported in the abstract
Weight loss ≥5%, ≥10%, ≥15% with tirzepatide
≥5% weight loss
78.22%
95% CI 72.15% to 83.73%
≥10% weight loss
55.60%
95% CI 46.54% to 64.47%
≥15% weight loss
32.28%
95% CI 23.17% to 42.12%
Further pooled results
| Outcome | MD (kg) (95% CI) | |
|---|---|---|
| Weight loss, tirzepatide 5 mgTirzepatidevs Placebo5 mg dose | −12.47 (−13.94 kg to −11.00 kg) | |
| Weight loss, tirzepatide 5 mgTirzepatidevs Semaglutide5 mg dose; n = 1409; SURPASS-2 trial | −1.90 (−2.97 kg to −0.83 kg) | |
| −20−10010Difference, kg (linear scale) |
Weight loss, tirzepatide 5 mg
- Dose-dependent increase in weight loss for 10 mg and 15 mg doses
Safety
- Increased odds of gastrointestinal adverse events (AEs) with tirzepatide vs placebo
- No significant difference in gastrointestinal AEs vs semaglutide
Original publication
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). Published 31 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →